By investigating the interplay between ANXA7 expression and BRAF mutation (V600E), our study offers promising insights into overcoming resistance to the BRAF V600E mutation or MAPK-targeting drugs in the treatment of thyroid cancer. The gene discussed is BRAF; the disease is thyroid cancer.